The threat of Antimicrobial Resistance in Developing Countries: Causes and Control Strategies

Umar Asiya Imam¹, Abdulqadir Zahrau¹ and *Emmanuel Ifeanyi Obeagu²

¹Department of Medical Microbiology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.
²Department of Medical Laboratory Science, Kampala International University, Uganda.
*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda. emmanuelobeagu@yahoo.com, obeagu.emmanuel@kIU.ac.UG 0000-0002-4538-0161

ABSTRACT

The causes of antimicrobial resistance (AMR) in developing countries are complex and may be rooted in practices of healthcare professionals and patients’ behavior towards the use of antimicrobials as well as supply chains of antimicrobials in the population. Some of these factors may include inappropriate prescription practices, inadequate patient education, limited diagnostic facilities, unauthorized sale of antimicrobials, lack of appropriate functioning drug regulatory mechanisms, and non-human use of antimicrobials such as in animal production. Considering that these factors in developing countries may vary from those in developed countries, intervention efforts in developing countries need to address the context and focus on the root causes specific to this part of the world. Here, we describe these health-seeking behaviors that lead to the threat of AMR and healthcare practices that drive the development of AMR in developing countries and we discuss alternatives for disease prevention as well as other treatment options worth exploring.

Keywords: Antimicrobial resistance, Causes and Control Strategies

INTRODUCTION

The threat of antimicrobial resistance (AMR) is growing at an alarming rate and the situation is perhaps aggravated in developing countries due to gross abuse in the use of antimicrobials [1-17]. It is well known that any use of antimicrobials however appropriate and justified, contributes to the development of resistance, but widespread unnecessary and excessive use makes the situation worse [18]. Misuse of antimicrobials is facilitated in developing countries by their availability over the counter, without prescription and through unregulated supply chains [19]. Non-compliance in the use of antimicrobials has many repercussions upon resistance and poverty is a major root factor of antimicrobial misuse in developing countries [20]. On the other hand, even among the rich, some patients miss doses either by mistake or deliberate, especially in cases where signs and symptoms begin to subside after an initial favorable therapeutic response [21]. In other situations, such as in the event of an acute side effect, patients abandon their treatment, only to return to the hospital with a recurring infection by a more virulent and resistant strain of the microbe [22]. These actions result in the exposure of surviving pathogens to sub-therapeutic concentrations of antimicrobials thus increasing the chances of acquiring resistance. Self-medication is a common practice in developing countries where patients often get antimicrobials without prescription and through unregulated supply chains [23]. To make the situation even worse, some patients seek their first-line of treatment from traditional healers who provide them with herbal combinations for the treatment of infections. These substances of unknown composition and potency may enhance pathogen fitness and contribute to the development of...
Responding to the threat of Antimicrobial Resistance

While AMR has long been recognized as a threat to human health, in recent years many countries have focused on reducing healthcare-acquired infections such as methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile* infection (CDI). This has led to a significant reduction in the incidence of both MRSA and CDI within hospitals in the UK and a major decline in prescribing of cephalosporins and fluoroquinolones. Arguably, this success has shifted attention away from AMR, allowing it to escalate. Despite concerted efforts from 1998 onwards, through a series of World Health Assembly (WHA) resolutions and the 2001 WHO global strategy for containment of AMR, the need to accelerate progress on AMR has been widely acknowledged by the WHO, the USA and the European commission. Though important for the UK, this action alone could not drive the collaborative response and commitment that was required from governments across the world. This demanded a strategic approach:

**Causes of antimicrobial resistance**

To better appreciate the causes of AMR, we need to understand the various sequential steps involved for a drug to get to a patient and the eventual use, which include; production, distribution, prescription, dispensing, and finally consumption of the drug by the patient or use in animal production. Consequently, any imprudent practice along this flow may result in the emergence of resistance.

1. **Drug dispensers and drug quality**

The lack of appropriate regulations in the sales of antimicrobials is also a driving factor in the access and misuse of antimicrobials. In most developing countries, antimicrobials can be purchased without medical prescription and are usually dispensed on the streets by untrained persons. These drug vendors will sell medications just to make a sale and accommodate patients’ ability to pay. Even pharmacies operating without a license, appear to be more accessible to the public as they have shorter waiting time, do not charge consultation fees and above all are willing to negotiate treatment options to adjust to the financial ability of the patients. Retail pharmacies in developing countries especially in Africa have emerged as the primary level of outpatient care rendering unauthorized services from consultation, diagnosis, prescription and dispensing of medication. It has also been shown that many antimicrobials dispensed in Africa are of questionable pharmacological quality. Adverse climatic conditions such as high ambient temperatures and humidity may affect the overall quality of the antimicrobials during storage. Poor storage also increases the risk of degradation of the drug. Degraded medicines contain less than stated dose, implying that patients consume less than optimal dose of the drug. There is also a problem of outright counterfeit, in which the drug may contain little or no active substance of the antimicrobial or the wrong substance.

2. **Health professionals**

Health care providers play an essential role in the treatment and prevention of diseases, but may jeopardize this if their practices are not evidence-based. For example, the prescription practices of antimicrobials vary among physicians in most countries. In some cases, the antimicrobial prescriptions are inappropriate (i.e., wrong drug, wrong doses, or antimicrobial not necessary at all). Due to the high patient-doctor ratio in most
As mentioned earlier, compliance is a major contributor to the development of AMR [36]. Patients miss doses, either by mistake or deliberate. Because patients are aware of the adverse impact of drinking alcohol while on antibiotics, some patients may skip doses when invited for a party in favor for the consumption of alcohol (unpublished data). These practices result in exposure of surviving microbes to sub-therapeutic concentrations of the drug and, consequently increases the chances of developing resistance [37]. Because of poverty, many sick individuals in developing countries of Africa often seek their first-line of treatment from traditional healers who provide them with herbal mixtures of unknown efficacy for the treatment of infections. Some combine antibiotics with their herbal mixtures simultaneously while others take antimicrobials and supplement them with herbal mixtures purportedly to improve efficacy [28]. These compounds of unknown potency may enhance pathogen fitness.

4. Non-human use of antimicrobials

Antimicrobials are used to prevent (prophylaxis in high-risk animals) and treat diseases in animals, as well as used as growth promoters in animal breeding [38–39]. Additionally, they are used as additives in plant agriculture (fruits, vegetables, and orchid, etc.), especially in the spraying of fruit trees for disease prophylaxis and the application of antibiotic-containing manure on farmland and in industrial processes [40]. The use of antimicrobial agents in animals and more importantly food-producing animals has important consequences for both human and animal health as it can lead to the development of resistant bacteria. These resistant bacteria (with resistance genes) in animals can be transferred to humans through the consumption of food or through direct contact with food-producing animals or through environmental spread (e.g., human sewage and runoff water from agricultural sites). The use of antimicrobial drugs in health care, agriculture or industrial settings, exerts a selection pressure which can favor the survival of resistant strains (or genes) over susceptible ones, leading to a relative increase in resistant bacteria within microbial communities [41]. It is now known that increased AMR in bacteria affecting humans and animals is primarily influenced by an increase in the use of antimicrobials for a variety of purposes, including therapeutic and non-therapeutic purposes in animal production (Food and Agriculture Organization). A strong association between agricultural use of antimicrobials and the development of resistance has been suggested [42], and it has been shown that the bulk of antimicrobials used worldwide are not consumed by humans but rather are given to animals for the purposes of food production [43]. A study in Kenya revealed a high level of antimicrobial drug residues in meat meant for consumption [44]. These findings further demonstrate that food animals are a major reservoir of drug resistant bacteria and present a major risk for dissemination and transmission of antimicrobial resistant bacteria in Africa as well as many developing countries. A large proportion of the population in developing countries live in close proximity with animals, thus increasing the chances of transmission of resistant microorganisms from animals to humans through animal handling [44–45]. In a recent study in rural Bangladesh animal healthcare providers responded they more often sought animal health care from pharmacies and village doctors, citing the latter two as less costly and more successful based on past performance [46]. In the absence of an effective animal healthcare system, villagers depend on informal healthcare providers for treatment of their animals. This may lead to suboptimal use of antimicrobials in such settings with unhygienic animal husbandry practices. In terms of aquaculture, heavy use of prophylactic antibiotics in aquaculture has been reported in developing countries and is a growing problem for human and animal health and for the environment [47]. Overall, limiting the routine use of in-feed antibiotics will improve human and animal health, by reducing the development and spread of antibiotic-resistant bacteria. Therefore, judicious use of antibiotics in healthcare and agricultural settings is essential to slow the emergence of resistance and extend the useful lifetime of effective antibiotics that are in existence today. In other to minimize the risk of AMR due to non-human use of antimicrobials especially in animal production, information resources in developing countries need to be strengthened to support health professionals, patients, animal keepers and the public, so that the society can have a better understanding of the value and importance of antimicrobials, especially antibiotics.
The availability of routine antimicrobial susceptibility testing to provide information on resistance trends, including emerging resistance is very essential for routine clinical practice and for the development of effective policies against AMR. Antimicrobial susceptibility testing is not often performed in most rural laboratories due to lack of capacity [48].

6. Inadequate surveillance

Antimicrobial resistance control strategies

The problem of AMR is aggravated by the fact that most world pharmaceutical companies consider research for new antimicrobials as being of “low profit” and some speculate that resistance will eventually develop for new antimicrobials anyway. Consequently, they prefer to invest in the development of drugs for chronic diseases (diabetes, hypertension) as well as those used to improve lifestyle (e.g., Cialis, Viagra, etc.) [49]. Therefore, the long-term solution should be focused on methods to prevent the emergence of resistance or the spread of resistant organisms from one person to another.

1. Hygiene and sanitation

While antimicrobials are used for treatment, vaccines are a primary mode of prevention of infectious diseases. Prior vaccination may reduce severity of disease, provide protection against shedding of pathogens and even raise the threshold load of pathogens required for infection [51-53]. Also, indirect population protection of some vaccines as a result of herd immunity in unvaccinated individuals represents additional advantage of vaccination. In most regions of the world, a number of diseases such as smallpox, measles, mumps rubella, diphtheria, hepatitis A, pertussis, and polio have been prevented by vaccination [54].

2. Vaccination

The increase in microbial resistance to traditional antimicrobials and the reluctance of pharmaceutical companies to invest in research and development of novel antimicrobial agents necessitate the exploration of alternative therapies. Future focus of medical therapeutics and research is to look beyond antibiotics [49], and search for alternatives which can regulate the microbial virulence as well as growth inhibition. There are currently a couple of other alternatives approaches at different levels of research and development.

1. The use of Bacteriophages is emerging as an alternative treatment option for bacteria infections [55]. Many authors have suggested that bacteriophage therapy is a necessary alternative to conventional antibiotics [56-57]. Bacteriophages are bacterial viruses with the capacity to invade bacterial cells and induce lysis of the bacteria (lytic cycle). In the present era of multidrug resistant bacteria and reluctance in the development of new antibiotics by pharmaceutical companies, the need to aggressively explore the possibility of phage therapy is unprecedented [58].

2. Quorum Sensing inhibitors represents an important antimicrobial target that may prevent, suppress, and/or treat infectious diseases. The mechanistic details (including auto-inducers) of Quorum Sensing are different between Gram-negative and Gram-positive bacteria. Gram-negative bacteria utilize N-acyl L-homoserine lactones (AHLs), which are homoserine lactone (HSL) rings with an additional fatty acid side chain while Gram positive bacteria uses oligopeptides [59-61]. While antibiotics kill or slow down the growth of bacteria, quorum sensing inhibitors or quorum quenchers simply attenuate bacterial virulence. A large body of work on Quorum Sensing has been carried out in deadly pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, Vibrio fischeri, Vibrio harveyi, Escherichia coli and Vibrio cholerae etc. A number of these studies have succeeded.
in exploiting the bacterial Quorum Sensing system as potential target for treatment of bacterial infections. The inhibition of Quorum Sensing system is believed to be advantageous over conventional antibiotics, because only the communication mechanism between the bacteria is disrupted without killing the individual cells. Hence, this strategy should generate a lower selective pressure and reduce the rate at which AMR develops during the treatment [61].

3. Probiotics, otherwise referred to as fecal transplant therapy (FTT) is a treatment option that has been employed for decades, albeit with mixed results. FTT is the act of using fecal material from pathogen-free healthy donors to repopulate the microbiota of a recipient. Probiotics are considered to be able to destroy pathogenic microorganisms by producing antimicrobial compounds such as bacteriocins and organic acids, improve gastrointestinal microbial environment by adherence to intestinal mucosa thereby preventing attachment of pathogens and competing with pathogens for nutrients, stimulate the intestinal immune responses and improve the digestion and absorption of nutrients.

The role of stakeholders in the control of antimicrobial resistance

The control of AMR cannot be the sole responsibility of medical professionals and scientists. Although continuing education is essential to enable health care providers learn the need in rational prescription practices and the importance of evidence-based prescription [62], the general population other stakeholders have a central role to play [63]. The government of every country should consider AMR as a public health priority issue. Policies and regulations should be put in place to enforce the prudent access and use of antimicrobials. The population needs to be educated on the threat of AMR and therefore media professionals need to get adequate training on how to convey medical and scientific information in lay language through multiple channels to inform the populations on practices that promote the emergence of AMR organisms [62]. The benefits of an education program for journalists have been successful for the fight against HIV/AIDS in many developing countries and a similar approach for AMR will likely result to an added benefit [64].

The role of government regulatory agencies

With the new and emergent issue regarding the development of AMR, government agencies globally have engaged in new action plans in order to combat the AMR issue [63-65]. However, actions toward this have been severely lacking in developing countries especially those in Africa where high-quality regulatory agencies are lacking. In May 2015, the WHO endorsed a global action plan to tackle AMR [65]. In September 2014, the US government released a “National Strategy for Combating Antibiotic-Resistant Bacteria” that included an executive order signed by the US president. The action plan provided several goals and a roadmap to guide the Nation in rising to this challenge. In 2015, the United Kingdom released the ‘UK Five Year Antimicrobial Resistance Strategy (2013 to 2018)’ that sets out actions to address the key challenges to AMR. Similarly, in 2015, the government of Canada also released the Federal Action Plan on antimicrobial resistance and use in Canada (Building on the federal framework for action). While many developed countries have developed such AMR action plans either nationally or at the regional level such as the European Union and Asia-Pacific region, this is still lacking in many developing countries especially in Africa [65]. A few African countries have been identified as being involved in the Global Antibiotic Resistance Partnership (GARP), established in 2009 to create a platform for developing actionable policy proposals on antibiotic resistance in low-income and middle-income countries. However, national GARP working groups are established only in India, Kenya, South Africa, Vietnam, Mozambique, Nepal, Tanzania and Uganda. Moreover, a close look at the national action plans showed that only one African country (Ethiopia), was identified by the WHO as having a national AMR action plan [27]. What most developing countries especially those in Africa lack is not the legislation prohibiting the manufacture and distribution of sub-standard drugs but resources to enforce these policies and to impose penalties to defaulters. There is also lack of resources to identify counterfeit drugs or verify the quality of locally manufactured or imported drugs [65]. In addition, governments need to address the sale of antimicrobials without prescription and illegalize the dispensing of drugs by unauthorized and unqualified persons. There is also need for the population to be sensitized on the public health risks of AMR. A recent WHO survey revealed that while much activity is underway and many governments are committed to addressing the AMR problem, there are major gaps in actions needed across all 6 WHO regions to prevent the misuse of antibiotics and reduce spread of AMR [65]. Despite these challenges some progress is currently being made in setting up drug regulatory agencies in Africa. The effort is supported by the New Partnership for Africa’s Development (NEPAD) of the African Union and the WHO. Through the creation of the African Medicines Regulatory
Harmonization (AMRH), it is envisioned that safe, good quality, efficacious and reasonably priced medicines will be available in Africa. Recently, the African Society for Laboratory Medicine (ASLM) has engaged in activities to share research, debate, and generate solutions to build a strong African laboratory infrastructure to help combat common

The irrational use of antimicrobials is certainly a complex and multifactorial problem in developing countries and a proper understanding of the problem is necessary for effective control policies. Without effective antimicrobials, diverse medical procedures such as surgery, the care of premature infants, cancer chemotherapy, care of the critically ill, invasive diagnostic and treatment procedures, and transplantation medicine will be severely hampered with a corresponding increase in morbidity and mortality from secondary microbial infections. The challenge of global antimicrobial resistance is comparable to climate change and global warming. Therefore, as we seek to protect the climate for the future generation, it is our responsibility not to pass over to the next generation, microbial population that is resistant to antimicrobial agents that they are supposed to treat as the consequence is likely to be very dangerous.

CONCLUSION

REFERENCES

1. Onemu, S. O., Ademulegun, F., Onemu-Metitiri, M. O., Obeagu, E. I., & Hassan, A. O. (2023). The contribution of curable plasmid-mediated resistance in isolates of staphylococcus aureus at the university of benin teaching hospital, Benin City, Nigeria. Asian Journal of Dental and Health Sciences, 3(3), 30-32.

2. Chukwueze, C. M., Okpala, O. V., & Obeagu, E. I. (2022). A systematic review on Methicillin resistant Staphylococcus aureus in patients with surgical wounds. Int. J. Adv. Multidiscip. Res, 9(9), 25-36.

3. Odo, E. O., Ikwuegbu, J. A., Obeagu, E. I., Chibueze, S. A., & Ochiaka, R. E. (2023). Analysis of the antibacterial effects of turmeric on particular bacteria. Medicine, 102(48), e96492.

4. Hasssan, A. O., Obeagu, E. I., & Olamijuewon, P. B. (2022). Evaluation of different microbial pathogens associated with the external surfaces of houseflies and to determine the antibiotic susceptibility pattern of recovered bacterial pathogens in Owo. Int. J. Curr. Res. Med. Sci, 8(1), 1-13.

5. Chukwueze, C. M., Obu, J. O., & Obeagu, E. I. (2023). Isolation and identification of bacteria from surgical wound attention at Enugu State University Teaching Hospital, Enugu. Int. J. Curr. Res. Chem. Pharm. Sci, 10(8), 35-48.

6. Ojo, B. O., Abdulrahman, O. A., Haassan, A. O., Obeagu, E. I., Olamijuewon, P. B., Oyeromi, B. O., … & Kelvin, U. (2022). Plasmid Profiling of Bacteria Associated with Gastroenteritis among Children in Owo, Ondo State. Asian Journal of Research and Reports in Gastroenterology, 6(2), 29–41.

7. Chukwueze, C. M., Udeani, T. K., Obeagu, E. I., Ikpenwa, J. N., & Nneka, A. (2022). Prevalence of Methicillin Resistant Staphylococcus aureus Infections among Hospitalized Wound Patients from Selected Tertiary Hospitals within Enugu Metropolis. Journal of Advances in Medical and Pharmaceutical Sciences, 24(3), 18–27.

8. Ene, I. F., Bessie Enweani, I., Obaji, M. U., & Obeagu, E. I. (2021). Evaluation of Antibacterial and Antifungal Activities of Crude Extract and Fractions of Morinda citrifolia Fruit on Multiple Drug Resistant Clinical Isolates. Journal of Pharmaceutical Research International, 33(48B), 25–31.

9. Chukwueze, C. M., Okpala, O. V., & Obeagu, E. I. (2022). Prevalence of Methicillin resistant Staphylococcus aureus in patients with surgical wounds attending Esuth, Parklane. Int. J. Adv. Multidiscip. Res, 9(9), 1-12.

10. Ifediora, A. C., Obeagu, E. I., Akahara, I. C., & Eguzouwa, U. P. (2016). Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov, 5(1), 68–82.

11. Umeaku, C. N., Otuadinma, R. N., Ochiabuto, O. M. T. B., Onwuasoanya, U. F., & Obeagu, E. I. (2019). Antimicrobial and health potentials of clay. European Journal of Pharmaceutical and Medical Research, 6(8), 25-31.

12. Obeagu, E. I. (2018). Phytochemical composition and antimicrobial properties of...
Garcinia kola (Bitter Kola) seed extract. Int. J. Curr. Res. Chem. Pharm. Sci, 5(11), 8-12.

13. Onemu, S. O., Ige, R. F., Onemu-Metitiri, M. O., Uyigue, P. O., & Obegbu, E. I. (2023). The prevalence of asymptomatic bacteriuria in pregnant women in Akure, Ondo State, Nigeria. DYSONA-Life Science, 1-8.

14. Jansen, K. U., & Anderson, A. S. (2018). The role of vaccines in fighting antimicrobial resistance (AMR). Human vaccines immuno therapeutics, 14(9), 2142-2149.

15. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al., (2013). Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 13:1057–98.

16. Rathnakar UP, Kumar Sharma N, Garg R, Unnikrishnan, Gopalakrishna HN, (2012). A Study on the Sale of Antimicrobial Agents without Prescription in Pharmacies in an Urban Area in South India. 6(6):951–4.

17. Goutard FL, Bordier M, Calba C, Erlacher-Vindel E, Gochez D, de Balogh K.(2017) Antimicrobial policy interventions in food animal production in South East Asia. BMJ;358:j3544.

18. Ayukekbong, J.A., Ntemgwa, M, Atabe, A.N., (2017). The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrobial Resistance & Infection Control, 6(1): 1-8.

19. Rodrigues, C.F., (2020). Self-medication with antibiotics in Maputo, Mozambique: practices, rationales and relationships. Palgrave Communications, 6(1), pp.1-12.

20. Fluit AC, Visser MR, Schmitz FJ., (2001). Molecular detection of antimicrobial resistance. Clin Microbiol Rev; 14:836–871.

21. Kohanski MA, Dwyer DJ, Collins JJ., (2010). How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol; 8:429–35.

22. Charani, E., McKee, M., Ahmad, R., Balasegaram, M., Bonacorsa, C., Merrett, G.B., Busse, R., Carter, V., Castro-Sanchez, E., Franklin, B.D. and Georgiou, P., (2021). Optimising antimicrobial use in humans—review of current evidence and an interdisciplinary consensus on key priorities for research. The Lancet Regional Health–Europe, 7, p.100161.

23. Lansang MA, Lucas-Aquino R, Tupasi TE, Mina VS, Salazar LS, Jaban N, Limjoco TT, Nisperos LE, Kunin CM., (1990). Purchase of antibiotics without prescription in Manalia, the Philippines. Inappropriate choices and doses. J Clin Epidemiol. 43:61–7.

24. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA., (2007). Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis; 13:1640–6.

25. Goel P, Ross-Degnan D, Berman P, Soumerai S., (1996). Retail pharmacies in developing countries: a behavior and intervention framework. Soc Sci Med;42:1155–61.

26. Kwena Z, Sharma A, Wamae N, Muga C, Bukusi E., (2008). Provider characteristics among staff providing care to sexually transmitted infection self-medicating patients in retail pharmacies in Kibera slum, Nairobi. Kenya Sex Transm Dis; 35:480–3

27. Basco LK., (2004). Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. AmJTrop Med Hyg; 70:245–50.

28. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ (2005). The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med; 2:e100.

29. Usluer G, Ozgunes I, Leblebicioglu H., (2005). Turkish antibiotic utilization study group. A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann Clin Microbiol Antimicrob; 4:16.

30. Saleh N, Awada S, Awwad R, Jibai S, Arkoul C, Zaïter L, et al., (2015). Evaluation of antibiotic prescription in the Lebanese community: a pilot study. Infect Ecol Epidemiol; 5:27094.

31. Mallertheiner P., (1993). Compliance, adverse events and antibiotic resistance in helicobacter pylori treatment. Scand J Gastroenterol; 28:34–7.

32. Calva J, Bojalil R., (1996). Antibiotic use in a periurban community in Mexico: a household and drugstore survey. Soc Sci Med; 42:1121–8.

33. Collignon P, Wegener HC, Braam P, Butler CD., (2005). The routine use of antibiotics to promote animal growth does little to benefit protein undernutrition in the developing world. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc Am; 41:1007–13.

34. Petersen A, Andersen JS, Kaewnak T, Somsiri T, Dalsgaard A., (2002). Impact of integrated fish farming on antimicrobial...
resistance in a pond environment. Appl Environ Microbiol; 68:6036–42.
35. Vidaver AK., (2002). Uses of antimicrobials in plant agriculture. Clin Infect Dis Off Publ Infect Dis Soc Am; 34(Suppl 3):S107–10.
36. Witte W., (1998). Medical consequences of antibiotic use in agriculture. Science; 279:996–7.
37. Aarestrup F., (2012). Sustainable farming: get pigs off antibiotics. Nature; 486:465–6.
38. Mitema ES, Kikuvi GM, Wegener IC, Stohr K., (2001). An assessment of antimicrobial consumption in food producing animals in Kenya. J Vet Pharmacol Ther; 24:385–90.
39. Doyle ME., (2015). Multidrug-resistant pathogens in the food supply. Foodborne Pathog Dis. 2015; 12:261–79.
40. Simango C, Rukure G., (1991). Potential sources of campylobacter species in the homes of farmworkers in Zimbabwe. J Trop Med Hyg; 94:388–92.
41. Roess AA, Winch PJ, Akhter A, Afroz D, Ali NA, Shah R, et al., (2015). Household animal and human medicine use and animal husbandry practices in rural Bangladesh: risk factors for emerging Zoonotic disease and antibiotic resistance. Zoonoses Public Health; 62:559–78.
42. Cabello FC (2006). Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol; 8:1137–44.
43. Brandenburg K, Schürholz T., (2015) Lack of new antiinfective agents: passing into the pre-antibiotic age? World J Biol Chem 6:71–7.
44. Smith MA, Garbharran H, Edwards MJ, O'Hara-Murdock P., (2004). Health promotion and disease prevention through sanitation education in south African Zulu and Xhosa women. J Transcult Nurs Off J Transcult Nurs Soc; 15:62–8.
45. Hinman AR, Orenstein WA., (2007). Adult immunization: what can we learn from the childhood immunization program? Clin Infect Dis Off Publ Infect Dis Soc Am; 44:1532–5.
46. Iglehart JK., (1983). Health policy report. The centers for disease control. N Engl J Med; 308:604–8.
47. Robinson CA, Bart KJ., (1993). Disease prevention through immunization: the beginning of health care reform. Public Health Rep; 108:417–8.
48. van Panhuis WG, Greffenstette J, Jung SY, Chok NS, Cross A, Eng H, et al., (2013). Contagious diseases in the United States from 1888 to the present. N Engl J Med; 369:2152–8.
49. Barrow PA, Soothill JS., (1997). Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol; 5:268–71.
50. Alisky J, Iezkowsi K, Rapoport A, Troitsky N., (1998). Bacteriophages show promise as antimicrobial agents. J Inf Secur ;36:5–15.
51. Mathur MD, Vaidhi S, Mehdiratta PL., (2003). Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India; 51:593–6.
52. Clark, J.R., (2015). Bacteriophages therapy: history and future prospects. Future Virology, 10(4): 449–461
53. Rasmussen TB, Givskov M., (2006). Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol IJMM; 296:149–61.
54. Williams P., (2007). Quorum sensing, communication and cross-kingdom signalling in the bacterial world. Microbiol Read Engl; 153:3923–38.
55. Waters CM, Bassler BL., (2005). Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol; 21:319–46.
56. Bhutta TI, Balchin C., (1996). Assessing the impact of a regulatory intervention in Pakistan. Soc Sci Med; 42:1195–202.
57. Blakely JT-M, Sinkowitz-Cochran RL, Jarvis WR., (2006). Infectious diseases physicians’ preferences for continuing medical education on antimicrobial resistance and other general topics. Infect Control Hosp Epidemiol.; 27:873–5.
58. Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA., (2008). Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries. J Int AIDS Soc.;11:2.
59. WHO. Global action plan on antimicrobial resistance. (2015).
60. Dua V, Kunin CM., (1994). White LV. The use of antimicrobial drugs in Nagpur, India. A window on medical care in a developing country. Soc Sci Med; 38:717–24.
61. Onyeze, R., Udeh, S. M., Akachi, B., & Ugwu, O. P. (2013). Isolation and characterization of fungi associated with the spoilage of corn (Zea Mays). *International Journal of Pharma Medicine and Biological Science, 2*(3), 86-91.

62. Ilozue, N. M., Ikezu, U. P., & Okechukwu, P. U. (2014). Antimicrobial and phytochemical screening of the seed extracts of Persea americana (avocado pear). *IOSR Journal of Pharmaceutical and Biological Sciences, 9*(2), 23-25.

63. Amalu, P. C., Chukwuezi, F. O., & Ugwu, O. P. C. (2014). Antimicrobial effects of bitter kola (Garcinia kola) nut on Staphylococcus aureus, Escherichia coli and Candida albicans. *Journal of Dental and Medical Sciences (IOSR-JDMS), 13*(4), 29-32.

64. Adonu, C. C., Esimone, C. O., Ugwu Okechukwu, P. C., Bawa, A., & Ossai, E. C. (2013). In vitro evaluation of the antibacterial potential of extracts of the aerial parts of Cassytha filiformis against urogenital clinical Gram positive organisms. *International Journal of Pharmaceutical Biological and Chemical Sciences, 2*(1), 01-09.

65. Chukwuezi Fabian, O., & Ugwu Okechukwu, P. (2014). Antimicrobial effects of bitter kola (Garcinia kola) nut on Staphylococcus aureus, Escherichia coli and Candida albicans. *Journal of Dental and Medical Sciences, 13*(4), 29-32.

CITE AS: Umar Asiya Imam, Abdulqadir Zahrau and Emmanuel Ifeanyi Obeagu (2024). The threat of Antimicrobial Resistance in Developing Countries: Causes and Control Strategies. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 9(1) 20-28. https://doi.org/10.59298/IDOSRJSR/2024/1.1.2028.100

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.